Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne
Lausanne's university hospital and Ludwig branch, home of the temozolomide glioblastoma trial, Solange Peters and a leading personalised T-cell therapy programme.
The CHUV Department of Oncology, headed by Solange Peters (ESMO president 2020-2021), works with the Ludwig Institute for Cancer Research Lausanne branch under George Coukos, the University of Lausanne, EPFL's ISREC institute and the Geneva hospitals within the Swiss Cancer Center Léman, housed in the AGORA research building opened in 2018. Roger Stupp led from Lausanne the EORTC/NCIC trial that made radiotherapy plus temozolomide the standard for glioblastoma, and Douglas Hanahan, author of 'The Hallmarks of Cancer', directed ISREC. The Ludwig groups run personalised tumour-infiltrating lymphocyte and neoantigen-targeted T-cell trials in ovarian and other cancers, and the hospital is a major thoracic oncology and immunotherapy trial site with a phase 1 unit.
- Ludwig Lausanne immuno-oncology
- Personalised TIL and T-cell therapy
- Thoracic oncology
- Neuro-oncology heritage
- Swiss Cancer Center Léman
Solange Peters is a lung cancer trialist and past ESMO President who led CheckMate 743 in mesothelioma.
Led the EORTC/NCIC trial that made temozolomide with radiotherapy the glioblastoma standard, and the EF-14 trial of tumour treating fields.
Pages like this
not linked directly; found by shared links- PairingPD-1 failure → TIL therapy
Shares TIL therapy, Pembrolizumab, Melanoma, Immune checkpoint inhibitors.
- InstitutionCentre hospitalier de l'Université de Montréal (CHUM)
Shares TIL therapy, Ovarian cancer, Melanoma, Immune checkpoint inhibitors.
- InstitutionComprehensive Cancer Center Tübingen-Stuttgart
Shares Neoantigen, TCR-T cell therapy, Personalised neoantigen (mRNA) vaccines, Glioma & glioblastoma.
- InstitutionMaria Skłodowska-Curie National Research Institute of Oncology
Shares EORTC, European Society for Medical Oncology (ESMO), Melanoma, Immune checkpoint inhibitors.
- PersonTimothy A. Chan
Shares Neoantigen, Melanoma, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PersonKellie N. Smith
Shares Neoantigen, Personalised neoantigen (mRNA) vaccines, Immune checkpoint inhibitors.
- InstitutionQIMR Berghofer Medical Research Institute
Shares TCR-T cell therapy, Glioma & glioblastoma, Ovarian cancer, Melanoma.
- InstitutionIRCCS Regina Elena National Cancer Institute
Shares Personalised neoantigen (mRNA) vaccines, Ovarian cancer, Melanoma, Immune checkpoint inhibitors.